Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 28 May 1993:
Vol. 260. no. 5112, pp. 1279 - 1286
DOI: 10.1126/science.8493572
Prev | Table of Contents | Next

Articles

Science, Vol 260, Issue 5112, 1279-1286
Copyright © 1993 by American Association for the Advancement of Science

articles

Scientific and social issues of human immunodeficiency virus vaccine development

BF Haynes

Duke University School of Medicine, Durham, NC.

Development of a preventive immunogen for human immunodeficiency virus (HIV) infection is a national priority. The complexities associated with HIV host-virus interactions, coupled with the rapid progression of the HIV epidemic worldwide, have necessitated lowering expectations for an HIV vaccine that is 100 percent effective and have raised important scientific and nonscientific issues regarding development and use of preventive and therapeutic HIV vaccines.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Are US Populations Appropriate for Trials of Human Immunodeficiency Virus Vaccine? : The HIVNET Vaccine Preparedness Study.
G. R. Seage III, S. E. Holte, D. Metzger, B. A. Koblin, M. Gross, C. Celum, M. Marmor, G. Woody, K. H. Mayer, C. Stevens, et al. (2001)
Am. J. Epidemiol. 153, 619-627
   Abstract »    Full Text »    PDF »
Comparison of the Antibody Repertoire Generated in Healthy Volunteers following Immunization with a Monomeric Recombinant gp120 Construct Derived from a CCR5/CXCR4-Using Human Immunodeficiency Virus Type 1 Isolate with Sera from Naturally Infected Individuals.
S. Beddows, S. Lister, R. Cheingsong, C. Bruck, and J. Weber (1999)
J. Virol. 73, 1740-1745
   Abstract »    Full Text »
A Dynamic HIV-Transmission Model for Evaluating the Costs and Benefits of Vaccine Programs.
D. M. Edwards, R. D. Shachter, and D. K. Owens (1998)
Interfaces 28, 144-166
   Abstract »    PDF »
Immunological and Virological Analyses of Persons Infected by Human Immunodeficiency Virus Type 1 while Participating in Trials of Recombinant gp120 Subunit Vaccines.
R. I. Connor, B. T. M. Korber, B. S. Graham, B. H. Hahn, D. D. Ho, B. D. Walker, A. U. Neumann, S. H. Vermund, J. Mestecky, S. Jackson, et al. (1998)
J. Virol. 72, 1552-1576
   Abstract »    Full Text »    PDF »
Using Factorial Surveys for Designing Intervention Programs.
M. Hennessy, K. M. MacQueen, and B. Seals (1995)
Eval Rev 19, 294-312
   Abstract »    PDF »
The next steps toward a global AIDS vaccine.
W. Koff (1994)
Science 266, 1335-1337
   PDF »
The role of interleukin-6 in mucosal IgA antibody responses in vivo.
A. Ramsay, A. Husband, I. Ramshaw, S Bao, K. Matthaei, G Koehler, and M Kopf (1994)
Science 264, 561-563
   Abstract »    PDF »
HIV Vaccines: A Magic Bullet in the Fight Against AIDS?.
S. D. Pinkerton and P. R. Abramson (1993)
Eval Rev 17, 579-602
   Abstract »    PDF »
Alloimmunization as an AIDS vaccine?.
G. Shearer, M Clerici, and A Dalgleish (1993)
Science 262, 161-162
   PDF »
A magic bullet against AIDS?.
S. Pinkerton and P. Abramson (1993)
Science 262, 162-163
   PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)